Current strategies for identification of glioma stem cells: adequate or unsatisfactory?
Current strategies for identification of glioma stem cells: adequate or unsatisfactory?
复制标题
DOI：
10.1155/2012/376894
复制
发表时间：
2012
影响因子：
--
通讯作者：
Pelicci G
中科院分区：
文献类型：
--
作者：
Brescia P;Richichi C;Pelicci G
癌症干细胞（CSCs）在多种肿瘤类型中被分离出来，包括人类胶质母细胞瘤，尽管在CSCs上选择性表达的表面标记物可以用于分离它们，但没有任何标记物/标记物模式足够强大，可以明确识别肿瘤中的干细胞。一些标记物的预后价值被评估，并获得了有希望的早期结果，但没有一个在大规模研究中被证明是临床有用的，这导致了识别新标记物的突出努力。鉴于人类胶质母细胞瘤的异质性，需要进一步的研究来确定癌症干细胞特异性标记和维持这些细胞致瘤潜力的分子机制，以开发量身定制的治疗方法。胶质母细胞瘤干细胞的标记物，如CD133、CD15、整合素-α6、L1CAM可能有助于识别这些细胞，但不能最终与干细胞表型联系起来。不同亚群的表达、功能状态和形态的重叠导致仔细考虑迄今为止所采用的分离这些细胞的技术。由于缺乏可靠地识别候选癌症干细胞的方法和标记，分离/富集用于治疗靶向的癌症干细胞仍然是一个主要挑战。
Cancer stem cells (CSCs) were isolated in multiple tumor types, including human glioblastomas, and although the presence of surface markers selectively expressed on CSCs can be used to isolate them, no marker/pattern of markers are sufficiently robust to definitively identify stem cells in tumors. Several markers were evaluated for their prognostic value with promising early results, however none of them was proven to be clinically useful in large-scale studies, leading to outstanding efforts to identify new markers. Given the heterogeneity of human glioblastomas further investigations are necessary to identify both cancer stem cell-specific markers and the molecular mechanisms sustaining the tumorigenic potential of these cells to develop tailored treatments. Markers for glioblastoma stem cells such as CD133, CD15, integrin-α6, L1CAM might be informative to identify these cells but cannot be conclusively linked to a stem cell phenotype. Overlap of expression, functional state and morphology of different subpopulations lead to carefully consider the techniques employed so far to isolate these cells. Due to a dearth of methods and markers reliably identifying the candidate cancer stem cells, the isolation/enrichment of cancer stem cells to be therapeutically targeted remains a major challenge.